Correction Notice: Evaluating Remimazolam for Sedation in ICU Settings

Overview

This correction notice addresses inaccuracies in author names in the article evaluating remimazolam for sedation in ICU settings. The correct names are provided for the second and third authors.

Background

Sedation in the ICU is a critical component of patient management. Remimazolam, an ultra-short-acting sedative, is being evaluated for its potential role in this context.

Data Highlights

No numerical or trial data is presented in the correction notice.

Key Findings

• The second author's name was incorrectly listed and should be corrected to 'Regis Goulart Rosa'.
• The third author's name should be accurately stated as 'Patricia Rodríguez-Villamizar'.
• The original article has been corrected to reflect these changes.

Clinical Implications

Accurate author attribution is essential for maintaining the integrity of scientific literature.

Conclusion

This correction ensures the proper acknowledgment of the authors involved in the study of remimazolam for ICU sedation.

Related Resources & Content

1. Critical Care Medicine, 2026 -- Correction Notice: Evaluating Remimazolam for Sedation in ICU Settings
2. Intensive Care Medicine — Remimazolam for ICU sedation: a genuine advance or a familiar story?
3. Intensive Care Medicine — Remimazolam besylate in the intensive care unit: emerging evidence, unresolved questions, and a potential clinical niche
4. Frontiers in Medicine — Clinical outcomes of a remimazolam-based sedation regimen in patients receiving ECMO: a retrospective comparative study
5. Frontiers in Neurology — Effects of Different Sedation Regimens on Delirium in ICU Patients
6. A Focused Update to SCCM PADIS Guidelines for Adult Patients | SCCM
7. Frontiers | Effect of remimazolam besylate versus midazolam on time to extubation in critically ill, mechanically ventilated patients: a randomized controlled trial